<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087460</url>
  </required_header>
  <id_info>
    <org_study_id>CS-CTP-PBPV-Ⅰa</org_study_id>
    <nct_id>NCT04087460</nct_id>
  </id_info>
  <brief_title>Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine</brief_title>
  <acronym>PⅠCTPV</acronym>
  <official_title>A Phase Ⅰa Randomized,Double-Blind, Placebo-controlled Clinical Trial to Preliminary Evaluate the Safety and Immunogenicity of Protein Based Pneumococcal Vaccine（PBPV） in Healthy People Aged Between 18 and 49 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CanSino Biologics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections with Streptococcus pneumoniae often cause serious health problems, especially for&#xD;
      infants and the elderly.Failure to cover all polysaccharide types is an even greater problem&#xD;
      with adults than with children.&#xD;
&#xD;
      The aim of the study is to preliminary evaluate the safety and immunogenicity of PBPV vaccine&#xD;
      compared to placebo,in order to provide a basis for subsequent clinical trial design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The polysaccharide vaccine protected 60% of elderly adults who were at risk for pneumococcal&#xD;
      infection.However, pneumococci are highly diverse with respect to their capsular types , and&#xD;
      the polysaccharide-protein conjugate vaccines will not protect against strains of the many&#xD;
      capsular types not included in the vaccine.This experimental vaccine was covered 70% of all&#xD;
      pneumococcal types, Subjects will receive three doses of PBPV vaccine on day 0,60 and 120&#xD;
      with different contents of 20μg,50μg,100μg each antigen in 18 to 49 years of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety indexes of solicited and unsolicited adverse reactions</measure>
    <time_frame>within 30 minutes,0-7 days,0-30 days post-vaccination</time_frame>
    <description>Occurrence of solicited and unsolicited reactions post each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety indexes of lab measures</measure>
    <time_frame>day 3 and 8 post the first vaccination</time_frame>
    <description>Occurrence of abnormal changes of hematological examination,clinical chemistry test,urine test and vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety indexes of lab measures</measure>
    <time_frame>day 14 and 30 post each vaccination</time_frame>
    <description>Occurrence of abnormal changes of CK-MB,CTN,urine test and vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety indexes of SAE</measure>
    <time_frame>within 180 days post vaccination</time_frame>
    <description>Occurrence of SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogencity indexes of GMC and GMI by ELISA</measure>
    <time_frame>day 8, 14,30,60 post each vaccination</time_frame>
    <description>Geometric mean concentration(GMC) and Geometric mean increase（GMI）of anti-PspA-RX1 , anti-PspA-3296, anti-PspA-5668 and anti-PlyLD antibodies in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogencity indexes of the seropositivity rates by ELISA</measure>
    <time_frame>day 8, 14,30,60 post each vaccination</time_frame>
    <description>the seropositivity rates of anti-PspA-RX1 , anti-PspA-3296, anti-PspA-5668 and anti-PlyLD antibodies in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>immunogencity indexes of GMT and GMI by Opsonophagocytic assay (OPA)</measure>
    <time_frame>day30,60 post each vaccination</time_frame>
    <description>Geometric mean titer(GMT) and Geometric mean increase（GMI）of antibodies in serum</description>
  </other_outcome>
  <other_outcome>
    <measure>immunogencity indexes of neutralization test</measure>
    <time_frame>day30,60 post each vaccination</time_frame>
    <description>neutralization test activity of anti-Ply antibody in serum</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pneumonia</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Low-dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of PBPV with 20μg each antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received three doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle-dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of PBPV with 50μg each antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle-dose Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received three doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of PBPV with 100μg each antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received three doses of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine(Low dose)</intervention_name>
    <description>0.2mL,Intramuscular other name:PBPV</description>
    <arm_group_label>Low-dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine placebo(Low dose)</intervention_name>
    <description>0.2mL,Intramuscular other name:PBPV placebo</description>
    <arm_group_label>Low-dose Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine(Middle dose)</intervention_name>
    <description>0.5mL,Intramuscular other name:PBPV</description>
    <arm_group_label>Middle-dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine placebo(Middle dose)</intervention_name>
    <description>0.5mL,Intramuscular other name:PBPV placebo</description>
    <arm_group_label>Middle-dose Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine(High dose)</intervention_name>
    <description>1.0mL,Intramuscular other name:PBPV</description>
    <arm_group_label>High-dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine placebo(High dose)</intervention_name>
    <description>1.0mL,Intramuscular other name:PBPV placebo</description>
    <arm_group_label>High-dose Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers aged 18 to 49 years old;&#xD;
&#xD;
          -  Willing to provide proof of identity;&#xD;
&#xD;
          -  Able to understand and sign the informed consent;&#xD;
&#xD;
          -  Able and willing comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertensive volunteers with uncontrollable medications (on-site measurement: systolic&#xD;
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg);&#xD;
&#xD;
          -  Abnormal changes of laboratory measures (with clinical significance);&#xD;
&#xD;
          -  Woman is pregnant and lactating (by urine pregnancy test)&#xD;
&#xD;
          -  Suffered from pneumonia in the past three years;&#xD;
&#xD;
          -  Invasive diseases caused by Streptococcus pneumoniae (such as meningitis, bacteremia,&#xD;
             pericarditis, peritonitis, etc.) in the past three years;&#xD;
&#xD;
          -  Allergic person;&#xD;
&#xD;
          -  Any prior administration of blood products in last 3 month;&#xD;
&#xD;
          -  Any prior administration of other research medicines in last 1 month;&#xD;
&#xD;
          -  Plans to participate in or is participating in any other drug clinical study;&#xD;
&#xD;
          -  Any prior administration of attenuated live vaccine in last 14 days;&#xD;
&#xD;
          -  Any prior administration of subunit or inactivated vaccines in last 7 days;&#xD;
&#xD;
          -  Had fever before vaccination, volunteers with temperature &gt;37.0℃ on axillary setting;&#xD;
&#xD;
          -  According to the investigator's judgment, the volunteers have any otherfactors that&#xD;
             make them unfit to participate in the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Shengli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Province Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suixian Center for Disease Control and Prevention</name>
      <address>
        <city>Shangqiu</city>
        <state>Henan</state>
        <zip>450016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccnie</keyword>
  <keyword>PspA</keyword>
  <keyword>Pneomolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In order to maintain the rights of the subject, do not open the IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

